Efficacy of fentanyl transdermal patch in pain control after lower third molar surgery: A preliminary study by Todorović, Vladimir S. et al.
Med Oral Patol Oral Cir Bucal. 2016 Sep 1;21 (5):e621-5.                                                                                                                                                          Fentanyl patch after third molar surgery
e621
Journal section: Oral Surgery
Publication Types: Research
Efficacy of fentanyl transdermal patch in pain control after 
lower third molar surgery: A preliminary study
Vladimir S. Todorovic 1, Miroslav Vasovic 2, Miroslav Andric 1, Ljubomir Todorovic 3, Vladimir Kokovic 4
1 Clinic of Oral Surgery, School of Dental Medicine, University of Belgrade, Serbia
2 Department of Dentistry, Faculty of Medical Sciences, University of Kragujevac, Serbia
3 Academy of Medical Sciences, Serbian Medical Society, Belgrade, Serbia
4 Advanced Europe Medical Centre, Dental Department, Sharjah. College of Dental Science, Ras Al Kaimah, UAE
Correspondence:
School of Dental Medicine 
University of Belgrade 
Serbia
todent@yahoo.com
Received: 19/11/2015
Accepted: 23/03/2016
Abstract
Background: Surgical removal of impacted lower third molars is a common oral surgical procedure, generally 
followed by moderate to severe postoperative pain. Transdermal drug delivery as a concept offers interesting pos-
sibilities for postoperative pain control. The aim of this study was to evaluate the efficacy of transdermal system 
with fentanyl in relieving pain following impacted lower third molar surgery. 
Material and Methods: Seventeen patients with bilateral impacted lower third molars were included in this pre-
liminary study. For postoperative pain control, patients randomly received a fentanyl patch plus placebo tablet 
after the first operation and regular (placebo) patch and an analgesic, after the second operation. Analgesia was 
evaluated during first 24 hours postoperatively according to patients’ reports about time of first pain appearance 
and additional analgesic consumption. Pain severity was rated using a 10 cm long visual analogue scale (VAS).
Results: Intensity of postoperative pain and postoperative analgesic consumption were significantly lower after 
the Fentanyl Transdermal System (FTS) was applied (p<0.05). Duration of postoperative analgesia was signifi-
cantly higher with FTS when compared to control treatment (p<0.05).
Conclusions: Based on the results of this preliminary study, transdermal system with fentanyl significantly re-
duced postoperative pain after third molar surgery.
Key words: Analgesia, fentanyl, transdermal administration, third molar surgery, acute pain, postoperative 
care.
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Introduction
Removal of impacted lower third molars is one of the 
most frequently performed oral surgical procedures. 
Regardless the difficulty of the procedure itself, it is 
still so often accompanied with postoperative pain that 
is usually used as a model for studying analgesic prop-
erties of several drugs or physical means (1,2). Despite 
general progress in pain management, moderate-to-
severe acute postoperative pain after removal of lower 
third molars remains a problem to be solved, in spite of 
many drugs and procedures suggested.
Transdermal drug delivery is not a new concept, but 
with interesting possibilities for postoperative pain 
control. Fentanyl was patented for use in a transdermal 
patch since 1984, and it has proven to be extremely ef-
fective in the treatment of severe chronic pain (3) and, 
interestingly, in the treatment of some postoperative 
pains (4,5). Fentanyl Transdermal System (FTS) is a 
rectangular transdermal patch containing a high con-
centration of fentanyl, a potent, short-acting Schedule II 
opiate (6). FTS includes a drug reservoir that contains 
Fentanyl in gel matrix, a release membrane that allows 
time- and surface-limited absorption of the drug, and an 
adhesive backing, providing a continuous systemic de-
livery of Fentanyl for 72 hours. It offers a prolonged and 
uniform analgesic effect, as well as euphoria and dys-
phoria (3). Patch dosage is 50 μg per hour. Because of its 
low molecular weight, high potency and lipid solubility, 
soon after application to intact skin, a Fentanyl depot 
concentrates in subcutaneous fat and it is then gradu-
ally released to the systemic circulation. Peek plasma 
concentration is reached between 24 and 72 hours of the 
treatment (7).  
The aim of this preliminary report was to present pos-
sible efficacy of transdermal Fentanyl application for 
managing postoperative pain after lower third molar 
surgery. 
  
Material and Methods
The present preliminary study was carried out at the 
Clinic of Oral surgery, School of Dental Medicine, Uni-
versity of Belgrade. After study approval by the local 
Ethics Committee (School od Dental Medicine, Univer-
sity of Belgrade, No. 36/10), 17 adult patients aged be-
tween 18 and 36 years, having bilaterally impacted low-
er third molars indicated for surgical removal, entered 
the study. Following thorough information, all patients 
subscribed the informed consent. Ethical approval ,Eth-
ics Committee of Faculty of Dental Medicine, Univer-
sity of Belgrade; No. 36/10.
Randomization was accomplished using envelope con-
taining random number of tooth and postoperative pain 
control protocol. Both, the operator and patients were 
blinded to the use of FTS. 
- Inclusion criteria
- Bilaterally identical position of impacted lower third 
molars;
- Good physical and mental condition (ASA I);
- Absence of infection (pericoronitis) or trauma prior 
to surgery.
- Exclusion criteria
- A history of allergy to the drugs used in the present 
study;
- A recent use of anti-inflammatory or antimicrobial 
drugs;
- The condition of being pregnant or lactating;
- Alcohol or narcotics abusers;
- Lack of compliance.
The lower third molars were evaluated on the panoram-
ic radiographs in order to confirm symmetrical position 
on both sides. Preoperative measurements included: 
mouth opening dimension, taken as the maximum dis-
tance between upper and lower central incisors, and fa-
cial cheek diameter, evaluated by measuring a distance 
between two reference points: tragus and pogonion. All 
the measurements were performed by a ruler and re-
corded as to the nearest mm.
- Surgical procedure
In each patient, surgical extractions of bilateral im-
pacted lower third molars were done in separate visits, 
the interval between surgeries being approximately two 
weeks. In order to avoid bias in manual skill, all surgical 
procedures were done by the same surgeon (first author). 
All the procedures were performed in local anesthesia 
using 2% lidocaine chloride with adrenaline 1:80.000 
(Lidokain-adrenalin®, Galenika a.d., Belgrade, Serbia), 
without any premedication or use of sedation during sur-
gery. After raising a mucoperiosteal flap from the buc-
cal aspect, a round bur with sterile saline irrigation was 
used to remove bone over the impacted tooth. If needed, 
sectioning of the crown and roots was performed before 
removing the tooth. The extraction wound was inspect-
ed and irrigated with sterile saline solution before sutur-
ing with a 4-0 suture. All the data concerning surgery 
were recorded, including the duration of surgery from 
the incision to placement of the last interrupted suture.
- Postoperative regimen and measurements
Postoperative pain control regimens were randomly di-
vided into two groups (FTS and control group). After 
the first operation, as the FTS group, all the patients re-
ceived a transdermal patch containing Fentanyl (FTS 
- Durogesic®, Janssen Pharmaceutics, Belgium) and a 
placebo tablet postoperatively. After the second opera-
tion, patients received a regular (placebo) patch and an 
analgesic tablet - a non-steroid anti-inflammatory drug 
(Diclofenac Duo® 75mg, Pharmaswiss, Czech Repub-
lic), orally once daily, representing a control regimen. 
Patients were advised to take an additional analgesic 
tablet as soon as their pain reached a moderate level, 
recording the exact moment of taking additional anal-
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gesic, so that we could count the elapsed time till the 
occurrence of pain. After each operation, patients were 
instructed to record the number of tablets used. 
Concerning antimicrobial therapy, all the patients were 
given amoxicillin 500 mg every 8 h orally for 5 days 
and advised to use chlorhexidine mouth rinse twice 
daily starting on the day after each operation for 10 fol-
lowing days. The patients were given usual postopera-
tive instructions. 
Each patient was evaluated at the follow-up control 24 
hours postoperatively. Postoperative pain was evalu-
ated using a 100 mm long visual analogue scale (VAS) 
with verbal descriptors “no pain” at the left end of the 
scale and “extremely severe pain” at the right end. The 
same examiner who assessed the patients preoperative-
ly performed clinical measurements during follow-up 
examinations. Trismus and facial edema, measured as 
stated previously, were recorded as the differences be-
tween preoperative (baseline) and postoperative (after 
24 hours) values.
- Statistical analysis
Statistical analysis was performed using the Statistical 
Package for Social Sciences (SPSS for Windows, ver-
sion 20.0; SPSS Inc., Chicago, IL, USA). The normal-
ity of the data was evaluated using Shapiro–Wilk test. 
Differences between two protocols were analyzed by 
Wilcoxon signed rank test for paired samples and the 
paired t-test, depending on data normality. Categorical 
variables were analyzed by χ2 test. Statistical differenc-
es between groups were accepted for p-values <0.05.
Results
Data from 17 patients (12 females, 5 males) were in-
cluded in the study, the mean age being 22.8 ± 4.2 
years. There was no statistically significant difference 
between study groups with regard to duration of sur-
gery in both sessions (Table 1). A postoperative course 
was uneventful in all patients. However, when received 
a transdermal patch containing Fentanyl (FTS), patients 
experienced postoperative pain much more rarely than 
after surgery when received only a non-steroid anti-in-
flammatory drug. 
With respect to pain evaluation by the VAS, there was 
a statistically significant difference between the FTS 
and the control group after 24 hours (Table 2). However, 
there was no statistically significant difference regard-
ing postoperative facial swelling and trismus between 
the groups.
Discussion
The impact that postoperative pain, among other postop-
erative sequels, has on patient quality of life after lower 
third molar surgery is undoubted. Of all the symptoms 
associated with this procedure, postoperative pain is 
one that patients apprise as the most inconvenient. In 
the literature, there are many articles regarding control 
       Parameter
Fentanyl Transdermal   
System
  Control group           P
Pain (VAS in mm)               0.9± 1.6        18.4 ±12.3       p<0.05
Swelling (mm)               6.9± 5.8          6.2 ±5.0         0.703
Trismus (mm)              11.2 ±9.1         11.9±7.9         0.623
Table 1. Summary of duration of surgery, postoperative pain and the need for additional analgesics postoperatively. 
*Paired-sample t-test, ǂ χ2 test.
Table 2. Pain, swelling and trismus 24 hours after each surgery in the investigated patients.    
(Mean ±SD).Wilcoxon signed-rank test.
Parameter
      Fentanyl Transdermal
               System
            Control group       p
Duration of surgery (min)
            Mean ± SD               Mean ± SD
  0.416*
             22.9  ±7.3                25.3 ± 9.9
Postoperative pain experience 
(Number of patients)
        YES
          1
       NO
        16
        YES
          13
        NO
          4  p<0.05ǂ
Need for additional analgesic
(Number of patients)
       YES
          1
       NO
        16
        YES
           8
        NO
          9  p<0.05ǂ
Elapsed time to the pain perceived
 (h) - mean ± SD                 4.0 ± 0.0                  7.7± 4.3 -
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of postoperative pain using various analgesics over time 
and comparing their efficacy. Theoretically, FTS could 
be an ideal drug for patients who are unable to eat due to 
severe trismus, swelling and especially for patients with 
gastrointestinal problems such as ulcer. 
Although the efficacy of FTS has already been proven 
in the treatment of chronic cancer pain (8-10), there have 
been relatively few reports evaluating the effectiveness 
of FTS for the treatment of acute postoperative pain. 
According to the best of our knowledge, there is not any 
report in the literature on use of FTS for pain control 
after lower third molar surgery. However, there are few 
considerations that have to be discussed.
Adverse events due to transdermal fentanyl use can be 
divided into three categories based largely on the intent 
of use: appropriate therapeutic use, inappropriate thera-
peutic use (misuse), and abuse. Abuse is defined as the 
intentional inappropriate use of the transdermal device, 
or its contents, for purposes other than those for which 
the transdermal device was intended or prescribed (11). 
This is typically done with euphoric intent, though it 
may occasionally be for suicidal reasons. Besides eu-
phoric intent, other side effects such as skin irritation, 
nausea, fever, headache and clinically relevant respira-
tory depression are also described in the literature (11). 
Case reports detail that elevation in skin or ambient 
temperatures from external sources, such as hot tubs or 
heating blankets, may lead to fentanyl overdose (12). In 
our study, patients were distinctly informed about the 
procedure and possible side effects, thus monitoring of 
each patient was organized in agreement with family 
member. In very few cases, nausea was reported, espe-
cially when patients were moving, which was stopped at 
moment of siting. Other side effects were not reported.
The recipient site on the skin that is most appropriate 
for application of FTS and its condition should also 
been discussed. The average skin thickness of the hu-
man body is 40 μm, but it ranges between 20 and 80 μm 
based on location, race, age, and gender, among other 
factors. In skin samples from 8 individuals, there was 
a >50% difference in the permeability of fentanyl (13). 
Skin surface areas with similar stratum corneum thick-
ness typically possess similar diffusion rates within an 
individual, explaining why the chest, extremities, and 
abdomen are acceptable sites for transdermal device 
application without the need for any dosage changes 
(13,14).
Also, following application of a transdermal fentanyl 
device to broken skin, blood fentanyl concentrations 
can rise 5-fold (15). In our study, as a recipient site, skin 
of the upper arm was used, after meticulous inspection 
of the area.
Recently, Fentanyl Iontophoretic Transdermal System 
(fentanyl ITS) was introduced as a system that has been 
approved especially for the management of acute, mod-
erate-to-severe postoperative pain (16). Fentanyl ITS is 
the first needle-free, self-contained, patient-activated 
system that delivers fentanyl directly through the skin 
by application of a low-intensity electrical field (17). 
Future investigations should consider the use of Fenta-
nyl ITS, as it allows patients to maintain an acceptable 
level of pain control following titration to comfort with 
a loading dose of opioid, while avoiding the first-pass 
effect and analgesic gaps associated with a delayed pas-
sive delivery using FTS patch. 
In conclusion, it can be stated that this preliminary re-
port found FTS to be very effective in relieving post-
operative pain after lower third molar surgery, with 
excellent tolerability. However, future clinical trials are 
necessary, with sufficient sample size and use of fenta-
nyl ITS, regarding possible standard use of opioids for 
control of acute pain after oral surgery.
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